2023
Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review
Doernberg S, Arias C, Altman D, Babiker A, Boucher H, Creech C, Cosgrove S, Evans S, Fowler V, Fritz S, Hamasaki T, Kelly B, Leal S, Liu C, Lodise T, Miller L, Munita J, Murray B, Pettigrew M, Ruffin F, Scheetz M, Shopsin B, Tran T, Turner N, Williams D, Zaharoff S, Holland T, Patel R, King H, Kinamon T, Dai W, Geres H, Deckard N, Schuler C, Bunn I, Sharma S, Wickward C, Waller J, Wilson H, Mehigan M, Ghazaryan V, Raterman E, Samuel T, Lee M. Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review. Clinical Infectious Diseases 2023, 77: s295-s304. PMID: 37843115, PMCID: PMC10578051, DOI: 10.1093/cid/ciad565.Peer-Reviewed Original ResearchConceptsAntibacterial Resistance Leadership GroupMRSA bloodstream infectionsMethicillin-resistant Staphylococcus aureusBloodstream infectionsClinical trialsPediatric community-acquired pneumoniaInfection researchEnterococcal bloodstream infectionsOptimal vancomycin dosingOptimization of dosingRole of dalbavancinCommunity-acquired pneumoniaShort-course therapyInterventional clinical trialsVancomycin-resistant enterococciVancomycin dosingPositive infectionsNovel agentsLife measuresTreat infectionsClinical practiceNarrative reviewInfectionPositive bacteriaStaphylococcus aureusThe Next Generation: Mentoring and Diversity in the Antibacterial Resistance Leadership Group
Harris A, Souli M, Pettigrew M, Group F. The Next Generation: Mentoring and Diversity in the Antibacterial Resistance Leadership Group. Clinical Infectious Diseases 2023, 77: s331-s335. PMID: 37843116, PMCID: PMC10578050, DOI: 10.1093/cid/ciad532.Peer-Reviewed Original Research
2022
Impact of antibiotics on off-target infant gut microbiota and resistance genes in cohort studies
Lebeaux RM, Madan JC, Nguyen QP, Coker MO, Dade EF, Moroishi Y, Palys TJ, Ross BD, Pettigrew MM, Morrison HG, Karagas MR, Hoen AG. Impact of antibiotics on off-target infant gut microbiota and resistance genes in cohort studies. Pediatric Research 2022, 92: 1757-1766. PMID: 35568730, PMCID: PMC9659678, DOI: 10.1038/s41390-022-02104-w.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsChildChild, PreschoolCohort StudiesEscherichia coliGastrointestinal MicrobiomeHumansInfantMicrobiotaConceptsAntibiotic exposureCohort studyDay careDay care attendanceInfant gut microbiotaAntibiotic resistance genesCare attendanceImpact of antibioticsAntibiotic useStool samplesGut microbiotaInfantsGut microbiomeStudy designBacteroides fragilisAntibioticsBackgroundYoung childrenNovel findingsSubsequent exposureExposureFirst yearFurther investigationBaselineResistance genesCareComparison of the Respiratory Resistomes and Microbiota in Children Receiving Short versus Standard Course Treatment for Community-Acquired Pneumonia
Pettigrew MM, Kwon J, Gent JF, Kong Y, Wade M, Williams DJ, Creech CB, Evans S, Pan Q, Walter EB, Martin JM, Gerber JS, Newland JG, Hofto ME, Staat MA, Fowler VG, Chambers HF, Huskins WC. Comparison of the Respiratory Resistomes and Microbiota in Children Receiving Short versus Standard Course Treatment for Community-Acquired Pneumonia. MBio 2022, 13: e00195-22. PMID: 35323040, PMCID: PMC9040816, DOI: 10.1128/mbio.00195-22.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsBeta-LactamsChildChild, PreschoolCommunity-Acquired InfectionsHumansInfantMicrobiotaPneumoniaConceptsCommunity-acquired pneumoniaShort-course strategyBeta-lactam therapyTreatment strategiesAntibiotic useRespiratory microbiomePediatric community-acquired pneumoniaDays of antibioticsShorter antibiotic coursesStandard-strategy groupDays of therapyStandard treatment strategyAntibiotic resistanceAdditional rationaleEffectiveness of interventionsImpact of durationAntibiotic coursesThroat swabsCourse strategyAntibiotic treatmentPediatric pneumoniaCourse treatmentLow prevalencePneumoniaAntibiotic resistance determinantsGastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia
Kwon J, Kong Y, Wade M, Williams DJ, Creech CB, Evans S, Walter EB, Martin JM, Gerber JS, Newland JG, Hofto ME, Staat MA, Chambers HF, Fowler VG, Huskins WC, Pettigrew M. Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia. The Journal Of Infectious Diseases 2022, 226: 1109-1119. PMID: 35249113, PMCID: PMC9492313, DOI: 10.1093/infdis/jiac082.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsBeta-LactamsChild, PreschoolCommunity-Acquired InfectionsDiarrheaGastrointestinal MicrobiomeHumansInfantPneumoniaConceptsAAD groupAntibiotic-Associated DiarrheaCommunity-Acquired PneumoniaCommon side effectsStudy days 1Days of diarrheaPatient characteristicsAntibiotic therapyNineteen childrenStool samplesSide effectsDay 1Microbiome disruptionMicrobiota profilesGastrointestinal microbiotaMicrobiota characteristicsDiarrheaBacteroides speciesPneumoniaChildrenAntibioticsΒ-lactamsAADBaseline abundanceDysbiosisShort- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children
Williams DJ, Creech CB, Walter EB, Martin JM, Gerber JS, Newland JG, Howard L, Hofto ME, Staat MA, Oler RE, Tuyishimire B, Conrad TM, Lee MS, Ghazaryan V, Pettigrew MM, Fowler VG, Chambers HF, Zaoutis TE, Evans S, Huskins WC, Team A. Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children. JAMA Pediatrics 2022, 176: 253-261. PMID: 35040920, PMCID: PMC8767493, DOI: 10.1001/jamapediatrics.2021.5547.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsChildChild, PreschoolCommunity-Acquired InfectionsDouble-Blind MethodFemaleHumansMaleOutpatientsPneumoniaConceptsChildhood community-acquired pneumoniaAntibiotic-associated adverse effectsShort-course strategyClinical responseAdverse effectsDouble-blind placebo-controlled clinical trialPlacebo-controlled clinical trialEnd pointDays of antibioticsEarly clinical improvementInadequate clinical responseOutpatient antibiotic therapyShorter antibiotic durationsSimilar clinical responseCommunity-Acquired PneumoniaPrimary end pointComposite end pointResolution of symptomsAntibiotic treatment strategiesSubset of childrenAntibiotic daysAntibiotic durationClinical improvementAntibiotic therapyInitial treatment
2021
Antibacterial Resistance Leadership Group 2.0: Back to Business
Chambers HF, Evans SR, Patel R, Cross HR, Harris AD, Doi Y, Boucher HW, van Duin D, Tsalik EL, Holland TL, Pettigrew MM, Tamma PD, Hodges KR, Souli M, Fowler VG. Antibacterial Resistance Leadership Group 2.0: Back to Business. Clinical Infectious Diseases 2021, 73: 730-739. PMID: 33588438, PMCID: PMC8366825, DOI: 10.1093/cid/ciab141.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsDrug Resistance, BacterialGram-Negative BacteriaGram-Positive BacteriaLeadership
2018
Gastrointestinal Microbiota Disruption and Risk of Colonization With Carbapenem-resistant Pseudomonas aeruginosa in Intensive Care Unit Patients
Pettigrew MM, Gent JF, Kong Y, Halpin AL, Pineles L, Harris AD, Johnson JK. Gastrointestinal Microbiota Disruption and Risk of Colonization With Carbapenem-resistant Pseudomonas aeruginosa in Intensive Care Unit Patients. Clinical Infectious Diseases 2018, 69: 604-613. PMID: 30383203, PMCID: PMC6669284, DOI: 10.1093/cid/ciy936.Peer-Reviewed Original ResearchConceptsCarbapenem-resistant Pseudomonas aeruginosaIntensive care unit patientsCare unit patientsPiperacillin-tazobactamUnit patientsICU patientsMarker of riskMaryland Medical CenterRisk of colonizationRibosomal RNA gene sequencingRNA gene sequencingAdmission swabCRPA infectionPseudomonas aeruginosaICU admissionPatient characteristicsMicrobiota disruptionMedical CenterGastrointestinal tractAdditional swabsAntimicrobial exposureLower riskEvaluated associationsPatientsProtective roleAzithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease
Tsuji BT, Fisher J, Boadi-Yeboah R, Holden PN, Sethi S, Pettigrew MM, Murphy TF. Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. Antimicrobial Agents And Chemotherapy 2018, 62: 10.1128/aac.01995-17. PMID: 29180527, PMCID: PMC5786777, DOI: 10.1128/aac.01995-17.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsAzithromycinHaemophilus InfectionsHaemophilus influenzaeHumansPulmonary Disease, Chronic ObstructiveRespiratory SystemConceptsChronic obstructive pulmonary disease patientsObstructive pulmonary disease patientsChronic obstructive pulmonary diseaseHollow-fiber infection modelStrains of NTHiPulmonary disease patientsObstructive pulmonary diseasePulmonary diseaseConcentration-dependent activityDisease patientsPharmacodynamic profilePharmacodynamic responseSame patientHaemophilus influenzaeInfection modelPatientsAzithromycinPersistent strainsDaysAirwayNTHiPharmacodynamicsInfluenzaeDiseaseHaemophilus
2017
Risk Factors and Outcomes Associated with Multidrug-Resistant Acinetobacter baumannii upon Intensive Care Unit Admission
Blanco N, Harris AD, Rock C, Johnson JK, Pineles L, Bonomo RA, Srinivasan A, Pettigrew MM, Thom KA. Risk Factors and Outcomes Associated with Multidrug-Resistant Acinetobacter baumannii upon Intensive Care Unit Admission. Antimicrobial Agents And Chemotherapy 2017, 62: 10.1128/aac.01631-17. PMID: 29133567, PMCID: PMC5740370, DOI: 10.1128/aac.01631-17.Peer-Reviewed Original ResearchConceptsMedical intensive care unitSurgical intensive care unitIntensive care unitICU admissionRisk factorsCare unitIntensive care unit admissionBroad-spectrum antibiotic useMultidrug-resistant Acinetobacter baumanniiPositive clinical cultureCare unit admissionRetrospective cohort analysisAssociated risk factorsEmpirical antibiotic selectionInfection control practicesPrevalence of MDRMaryland Medical CenterPerirectal surveillance culturesImportant nosocomial pathogenUnit admissionAdult patientsICU typePrevious admissionsCurrent hospitalizationActive surveillance
2016
Antimicrobial activity of antisense peptide–peptide nucleic acid conjugates against non-typeable Haemophilus influenzae in planktonic and biofilm forms
Otsuka T, Brauer AL, Kirkham C, Sully EK, Pettigrew MM, Kong Y, Geller BL, Murphy TF. Antimicrobial activity of antisense peptide–peptide nucleic acid conjugates against non-typeable Haemophilus influenzae in planktonic and biofilm forms. Journal Of Antimicrobial Chemotherapy 2016, 72: 137-144. PMID: 27986898, PMCID: PMC5161047, DOI: 10.1093/jac/dkw384.Peer-Reviewed Original ResearchEffect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease
Pettigrew MM, Tsuji BT, Gent JF, Kong Y, Holden PN, Sethi S, Murphy TF. Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. Antimicrobial Agents And Chemotherapy 2016, 60: 4151-4158. PMID: 27139476, PMCID: PMC4914697, DOI: 10.1128/aac.00301-16.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseH. influenzae isolatesH. influenzaePulmonary diseaseFluoroquinolone administrationInfluenzae isolatesDevelopment of resistanceHaemophilus influenzaeEradication of carriageEffects of macrolidesQuinolone resistance-determining regionsMICs of antibioticsEffects of fluoroquinolonesResistance-determining regionMacrolide administrationCOPD patientsEffects of antibioticsAzithromycin MICsAntibiotic useSusceptibility breakpointsAntibiotic susceptibilityMacrolide susceptibilityInfluenzaeAdministrationThe human microbiota: novel targets for hospital-acquired infections and antibiotic resistance
Pettigrew MM, Johnson JK, Harris AD. The human microbiota: novel targets for hospital-acquired infections and antibiotic resistance. Annals Of Epidemiology 2016, 26: 342-347. PMID: 26994507, PMCID: PMC4892961, DOI: 10.1016/j.annepidem.2016.02.007.Peer-Reviewed Original ResearchConceptsMultidrug-resistant organismsSpread of MDROsInfection control interventionsHealth care settingsCare settingsColonization resistanceControl interventionsTraditional infection control measuresInfection control measuresAntibiotic resistanceControl of MDROsHospital-acquired infectionsHealth care professionalsHospitalized patientsIntact microbiotaAntibiotic useMDRO transmissionEpidemiologic studiesInfection controlAntimicrobial stewardshipCare professionalsHealthy microbiotaExpansion of pathogensResistant organismsNovel targetPseudomonas aeruginosa Colonization in the Intensive Care Unit: Prevalence, Risk Factors, and Clinical Outcomes
Harris AD, Jackson SS, Robinson G, Pineles L, Leekha S, Thom KA, Wang Y, Doll M, Pettigrew MM, Johnson JK. Pseudomonas aeruginosa Colonization in the Intensive Care Unit: Prevalence, Risk Factors, and Clinical Outcomes. Infection Control And Hospital Epidemiology 2016, 37: 544-548. PMID: 26832307, PMCID: PMC4833506, DOI: 10.1017/ice.2015.346.Peer-Reviewed Original ResearchConceptsIntensive care unitPseudomonas aeruginosa colonizationRisk factorsICU admissionClinical culturesCurrent hospitalizationAeruginosa colonizationCare unitIntensive care unit admissionP. aeruginosaSurgical intensive care unitPositive clinical cultureCare unit admissionEmpirical antibiotic therapyTertiary care hospitalType of ICUSignificant risk factorsP. aeruginosa colonizationRapid diagnostic testingPerirectal surveillance culturesUnit admissionCohort studyAntibiotic therapyCare hospitalClinical outcomes
2014
Antibacterial Resistance Leadership Group: Open for Business
Chambers HF, Bartlett JG, Bonomo RA, Chiou C, Cosgrove SE, Cross HR, Daum RS, Downing M, Evans SR, Knisely J, Kreiswirth BN, Lautenbach E, Mickley BS, Patel R, Pettigrew MM, Rodvold KA, Spellberg B, Fowler VG. Antibacterial Resistance Leadership Group: Open for Business. Clinical Infectious Diseases 2014, 58: 1571-1576. PMID: 24610430, PMCID: PMC4017892, DOI: 10.1093/cid/ciu132.Peer-Reviewed Original ResearchConceptsAntibacterial Resistance Leadership GroupAntibacterial resistanceClinical research agendaPublic health threatClinical research opportunitiesInfection preventionClinical studiesAntimicrobial stewardshipClinical research proposalsInfectious diseasesClinical researchHealth threatNational InstituteInfectionMedical practiceHigh priority areasNegative bacteriaPositive bacteriaAllergyDiseasePrevention
2012
Upper Respiratory Tract Microbial Communities, Acute Otitis Media Pathogens, and Antibiotic Use in Healthy and Sick Children
Pettigrew MM, Laufer AS, Gent JF, Kong Y, Fennie KP, Metlay JP. Upper Respiratory Tract Microbial Communities, Acute Otitis Media Pathogens, and Antibiotic Use in Healthy and Sick Children. Applied And Environmental Microbiology 2012, 78: 6262-6270. PMID: 22752171, PMCID: PMC3416608, DOI: 10.1128/aem.01051-12.Peer-Reviewed Original ResearchConceptsAcute otitis mediaAntibiotic useS. pneumoniaeHealthy childrenM. catarrhalisH. influenzaeAcute otitis media pathogensConcurrent acute otitis mediaUpper respiratory tract infectionRespiratory tract infectionsOtitis media pathogensUpper respiratory tractCross-sectional studyYears of ageAOM pathogensTract infectionsOtitis mediaMoraxella catarrhalisRespiratory tractReal-time PCRNasal swabsSick childrenPrevention strategiesHaemophilus influenzaeStreptococcus pneumoniae
2011
Streptococcus pneumoniae Serotype 6C: an Intra- and Interclonal Complex Comparison
Thomas JC, Kong Y, Sabharwal V, Pelton SI, Pettigrew MM. Streptococcus pneumoniae Serotype 6C: an Intra- and Interclonal Complex Comparison. Journal Of Bacteriology 2011, 193: 3409-3410. PMID: 21551297, PMCID: PMC3133277, DOI: 10.1128/jb.05079-11.Peer-Reviewed Original ResearchBehavioural sources of repeat Chlamydia trachomatis infections: importance of different sex partners
Niccolai LM, Livingston KA, Laufer AS, Pettigrew MM. Behavioural sources of repeat Chlamydia trachomatis infections: importance of different sex partners. Sexually Transmitted Infections 2011, 87: 248. PMID: 21212380, PMCID: PMC5438152, DOI: 10.1136/sti.2010.045484.Peer-Reviewed Original ResearchConceptsChlamydia trachomatis infectionRepeat infectionsNew sex partnerTrachomatis infectionSex partnersC. trachomatisRepeat Chlamydia trachomatis infectionsPopulation attributable risk percentageC. trachomatis infectionCumulative incidenceDifferent-sex partnersRisk percentageYounger ageInfectionBehavioral surveyBaselineDifferent genotypesTrachomatisWomenMolecular methodsGenotypesPatientsFollowIncidence
2000
Wolbachia neither induces nor suppresses transcripts encoding antimicrobial peptides
Bourtzis K, Pettigrew M, O’Neill S. Wolbachia neither induces nor suppresses transcripts encoding antimicrobial peptides. Insect Molecular Biology 2000, 9: 635-639. PMID: 11122472, DOI: 10.1046/j.1365-2583.2000.00224.x.Peer-Reviewed Original ResearchConceptsInsect speciesCytoplasmic incompatibilityDifferent tissue tropismsSingle WolbachiaDefensin genesAntibacterial genesArthropod speciesAnopheles gambiaeWolbachiaExpression patternsMosquito speciesSpeciesGenesMosquito defensinUbiquitous parasiteHost immune systemImmune systemTissue tropismAntimicrobial peptidesTranscriptionAedes aegyptiAedes albopictusReproductive abnormalitiesDrosophilaParthenogenesis